Phase 2Data readout

Efzofitimod

Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

ATYRaTyr Pharma, Inc

Expected catalystMarch 31, 2027Company guidance: Mar 31, 2027

Catalyst overview

Event details

Drug or asset: Efzofitimod
Development stage: Phase 2
Event type: Data readout
Indication: Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). The expected timing is based on the latest available company guidance and may change.

Development notes

05/15/26:- EFZO-CONNECT Ph2 enrollment remains on track to complete in H1 2026. 08/07/26:- EFZO-CONNECT enrollment completed; topline Ph2 results expected in Q1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source